Kite targets HPV-related cancers with TCR deal; Emergent Bio licenses Ligand's antibody tech;

@FierceBiotech: BU group spotlights a lethal cascade that leads to Parkinson's. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: When has Pfizer ever won an R&D marathon in the last decade? | Follow @JohnCFierce

> Kite Pharma ($KITE), developing immunotherapies for cancer, signed a deal with the Netherlands' Leiden University Medical Center to collaborate on T cell receptor treatments for solid tumors related to HPV. More

> Emergent BioSolutions ($EBS) licensed Ligand Pharmaceuticals' ($LGND) R&D technology in hopes of crafting new antibody therapies. Item

> DelMar Pharmaceuticals is partnering with the University of Texas' MD Anderson Cancer Center to accelerate the development of its VAL-083 in brain cancer. News

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic earns CE mark to use its drug-eluting balloon to help hemodialysis patients. Article | Follow @FierceMedDev

@EmilyWFierce: Zoetis slammed with up to $45M charge after EU ruling on Belgian tax scheme. FierceAnimalHealth story | Follow @EmilyWFierce

> In a win for LivaNova, the FDA approves the world's only sutureless aortic valve. Article

Pharma News

@FiercePharma: Will pharma marketing to Hispanics finally gain traction in 2016? FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: Bayer's new plant in China will make both traditional Chinese meds and western OTC meds. FiercePharmaManufacturing report | Follow @EricPFierce

> Shire CEO thinks he can beat $500M in post-merger cost savings. More

> Depomed isn't anti-takeover, CEO says. It was just anti-Horizon. Article

Pharma Marketing News

> Will pharma marketing to Hispanics finally gain traction in 2016? More

> To flip the pricing debate, Big Pharma needs to tell some secrets. Story

> Look out, CLL. AbbVie and Roche's new venetoclax is on FDA's priority track. More

> Can Shire make the most of Baxalta's hemophilia meds? Item

> GSK's Slaoui sees 'major' vaccine market disruption for Merck as shingles candidate progresses. Article

Biotech Research News

> Cold Spring Harbor scientists develop a new drug for breast cancer. Report

> Johns Hopkins flags another possible successor to 'Special K' for depression. Story

> BU group spotlights a lethal cascade that leads to Parkinson's. More

> Slashing p75 neurotrophin receptor reduces obesity in mice: Gladstone. Article

> EPFL team creates an industrial-scale platform for stem cells. Item

Vaccines News

> Nearly a year into Novartis integration, GSK CEO won't discount vaccines spinoff. Report

> Aimmune takes peanut allergy vaccine into PhIII. More

> WHO seeks to ease cholera vaccine shortage with EuBiologics approval. Story

> Deal in Russia could cause Pfizer, GSK to lose contracts. Item

> New HIV vaccine player Aelix Therapeutics hits the scene with $12.7M Series A. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.